Evidence map›Paper›PMID 37624082›Full record

ArticlePharmacy (Basel, Switzerland)2023

Community Pharmacies in the Asian Countries of Developing Health System: Formation, Regulation, and Implication.

Shaymaa Alenezi, Mona Alanazi, Reaam Aljazaeri, Marwah Almuzaini, Shorouq Alrasheidi, Wafa Bin Shamlan, Raghad Aljohani, Ghadeer Alhawiti, Meaad Alqarni, Ehdaa Aljabri and 2 more

Abstract read
In one paragraph

Article in Pharmacy (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Prescription-only medicine requests by clients: Insights from community pharmacies.Exploratory research in clinical and social pharmacy · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Assessment of the feasibility of including community pharmacies under the regulation of the saudi food and drug authority.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shaymaa AleneziAl-Dawaa Pharmacy, Raiydh 12211, Saudi Arabia.
Mona AlanaziDepartment of Clinical Pharmacy, Nahdi Medical Co., Riyadh 13515, Saudi Arabia.
Reaam AljazaeriDepartment of Clinical Pharmacy, Nahdi Medical Co., Riyadh 13515, Saudi Arabia.ORCID 0000-0002-4373-9003
Marwah AlmuzainiAl-Dawaa Pharmacy, Raiydh 12211, Saudi Arabia.
Shorouq AlrasheidiAl-Dawaa Pharmacy, Raiydh 12211, Saudi Arabia.
Wafa Bin ShamlanCommunity Pharmacist, United Pharmaceutical Company, Jeddah 22230, Saudi Arabia.ORCID 0009-0008-2506-7566
Raghad AljohaniDepartment of Clinical Pharmacy, Nahdi Medical Co., Riyadh 13515, Saudi Arabia.
Ghadeer AlhawitiDepartment of Clinical Pharmacy, Alkadi Medical Group, Tabuk 47311, Saudi Arabia.
Meaad AlqarniDepartment of Clinical Pharmacy, Nahdi Medical Co., Riyadh 13515, Saudi Arabia.
Ehdaa AljabriDepartment of Clinical Pharmacy, Nahdi Medical Co., Riyadh 13515, Saudi Arabia.
Majd QmmashCollege of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia.
Mohammed KananDepartment of Clinical Pharmacy, King Fahad Medical City, Riyadh 12211, Saudi Arabia.ORCID 0000-0001-6687-0461

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Community pharmacies (CPs) in Asian countries are often the first point of contact for patients withinthe healthcare system and their preferred place to purchase medicines. The number of CPs may vary across Asian countries, and each country has developed its own design and functioning. The regulatory environment plays a crucial role in shaping and governing CPs. The aim of this study was to conduct a comprehensive literature review in order to enhance understanding of the establishment and regulation of CPs. By undertaking this review, the researchers, policymakers, and practitioners sought to gain a deeper insight into the performance and functions of CPs and the regulatory frameworks that govern them. Moreover, this review shed light on implementation strategies, effects on patient outcomes, and the barriers and challenges associated with their establishment. A narrative literature review method was adopted with specific inclusion and exclusion criteria. Significant disparities can be observed when comparing the stated intentions of regulations with their actual implementation. Recently, there has been an inclusion of public health practices. Unfortunately, pharmacy procedures conducted in such environments have been characterized by inadequate understanding and inappropriate care. This poor performance can be attributed to employees' focus on maximizing profits. Several shortcomings can arise, including incomplete patient history documentation, failure to refer patients who require medical attention, unauthorized dispensing of prescription-only medicines (POM), dispensing clinically inappropriate or excessive medication doses, selling incomplete antibiotic courses, and inadequate information and counseling services. Regulatory interventions can help strengthen these services.

Indexed as

Asiacommunity pharmaciesdeveloping countriesformation

Identifiers

PMID37624082
PMCPMC10460015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.